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The	  skeletal	  muscle	  ryanodine	  receptor	  isoform	  1	  (RyR1)	  is	  a	  calcium	  release	  channel	  involved	  in	  22 
excitation-­‐contraction	   coupling,	   the	   process	   whereby	   an	   action	   potential	   is	   translated	   to	   a	  23 
cytoplasmic	   Ca2+	   signal	   that	   activates	  muscle	   contraction.	   Dominant	   and	   recessive	  mutations	   in	  24 
RYR1	   cause	  a	   range	  of	  muscle	  disorders,	   including	  malignant	  hyperthermia	  and	  several	   forms	  of	  25 
congenital	   myopathies.	   Many	   aspects	   of	   disease	   pathogenesis	   in	   ryanodinopathies	   remain	  26 
uncertain,	   particularly	   for	   those	   myopathies	   due	   to	   recessive	   mutations.	   A	   thorough	  27 
understanding	   of	   the	   ryanodine	   receptor	   macromolecular	   complex	   and	   its	   interactions	   with	  28 
proteins	  and	  small	  molecular	  modulators	   is	  an	  essential	  starting	  point	   from	  which	  to	   investigate	  29 
disease	  mechanisms.	  	  30 
	  31 







Rapid	   changes	   in	   the	   intracellular	   calcium	  concentration	   ([Ca2+]i)	   are	   important	   signalling	  2 
events	   in	  most	   eukaryotic	   cells,	   necessitating	   tight	   regulation	   of	   cytoplasmic	   Ca2+	   levels.	   Global	  3 
increases	   in	   [Ca2+]i	   are	   triggered	   by	   the	   release	   of	   Ca2+	   from	   the	   endoplasmic	   reticulum	  4 
(ER)/sarcoplasmic	   reticulum	   (SR)	   intracellular	   stores	   and/or	   by	   calcium	   influx	   from	   the	  5 
extracellular	   environment	   via	   opening	   of	   specific	   plasma	   membrane	   channels.	   The	   primary	  6 
organelle	   involved	   in	   storing	   rapidly	   releasable	   Ca2+	   is	   the	   SR	   in	   striated	  muscles	   and	   the	   ER	   in	  7 
most	  other	  mammalian	   cell	   types.	   Two	   families	  of	   channels	   are	   responsible	   for	  mediating	   rapid	  8 
calcium	   release	   from	   these	   intracellular	   stores:	   ryanodine	   receptors	   (RyRs)	   which	   are	  9 
predominantly	  expressed	  in	  excitable	  cells	  and	  inositol	  1,4,5-­‐triphosphate	  receptors	  (IP3Rs)	  which	  10 
are	  expressed	  in	  most	  cells.	  11 
The	   skeletal	   muscle	   SR	   calcium	   release	   channel	   protein	   was	   first	   identified	   at	   the	  12 
biochemical	  level	  in	  the	  1980s	  and	  was	  named	  for	  its	  ability	  to	  bind	  the	  plant	  alkaloid	  ryanodine.	  13 
Three	   RyR	   isoforms,	   encoded	   by	   separate	   genes	   sharing	   a	   high	   level	   of	   homology,	   have	   been	  14 
identified	   in	   mammalian	   tissues.	   Ryanodine	   receptor	   type	   1	   (RyR1)	   is	   the	   primary	   isoform	  15 
expressed	  in	  skeletal	  muscle.	  RyR1	  is	  also	  expressed	  in	  some	  areas	  of	  the	  central	  nervous	  system	  16 
and	   in	   some	   haemopoietic	   cells.	   RyR2	   is	   the	   predominant	   isoform	   in	   cardiac	   muscle	   and	   is	  17 
expressed	   in	   various	   regions	  of	   the	  brain	  whereas	  RyR3	  has	  widespread	  expression,	   particularly	  18 
during	  development.	   In	   skeletal	  muscle,	  RyR1	   is	   a	   key	  protein	   involved	   in	  excitation-­‐contraction	  19 
(EC)	  coupling.	  In	  a	  simplified	  overview	  of	  this	  process,	  an	  electrical	  signal	  generated	  by	  an	  action	  20 
potential	   travelling	   along	   the	   transverse	   (t)-­‐tubules	   is	   detected	   by	   the	   dihydropyridine	   receptor	  21 
(DHPR),	  a	  voltage-­‐sensitive	  Ca2+	  channel.	  In	  response	  to	  membrane	  depolarization,	  DHPR	  channels	  22 
undergo	   a	   conformational	   change	   and	   induce	   the	   opening	   of	   RyR1	   channels	   that	   are	   closely	  23 
apposed	  and	  located	  on	  the	  SR	  terminal	  cisternae.	  This	  leads	  to	  the	  release	  of	  Ca2+	  from	  SR	  stores	  24 
into	   the	   cytoplasm.	   The	   cytoplasmic	   Ca2+	   binds	   to	   troponin	   and	   initiates	  muscle	   contraction	   in	  25 
sarcomeres.	  Muscle	  contraction	  is	  terminated	  upon	  closure	  of	  RyR1	  and	  reuptake	  of	  Ca2+	  from	  the	  26 
cytoplasm	  into	  the	  SR	  by	  sarcoplasmic/endoplasmic	  Ca2+	  ATPase	  (SERCA)	  pumps.	  27 
Ablation	  of	  RyR1	   in	  mice	  (dyspedic	  mice)	  results	   in	  a	   lethal	  phenotype	  most	   likely	  due	  to	  28 
respiratory	   failure.	   Mutant	   neonates	   also	   display	   skeletal	   abnormalities,	   including	   spined	  29 
curvature,	  arched	  vertebral	  column,	  thin	  limbs	  and	  a	  thick	  neck,	  and	  resembled	  dysgenic	  mice	  that	  30 
lack	  DHPR	  [1].	  Primary	  dyspedic	  muscle	  cell	   cultures	  exhibit	   severely	   impaired	  Ca2+	   release	  after	  31 






past	  decades	   it	  has	  emerged	  that,	  mutations	   in	  RYR1	  are	  a	  major	  cause	  of	  muscle	  disease.	  Both	  1 
dominant	   and	   recessive	  mutations	   have	   been	   identified	   throughout	   the	  RYR1	   coding	   sequence	  2 
and	  are	  responsible	  for	  a	  wide	  range	  of	  muscle	  disorders	  including	  malignant	  hyperthermia	  (MH),	  3 
central	   core	  disease	   (CCD),	  multi-­‐minicore	  disease,	   centronuclear	  myopathy,	   core-­‐rod	  myopathy	  4 
and	   congenital	   fiber	   type	   disproportion	   (Box	   1)	   [2-­‐4].	   Dantrolene,	   used	   in	   the	   emergency	  5 
treatment	   of	   malignant	   hyperthermia,	   is	   currently	   the	   only	   clinically	   relevant	   drug	   for	   RyR1	  6 
disorders	  and	  drugs	  that	  address	  the	  chronic,	  often	   life-­‐threatening	  muscle	  weakness	  associated	  7 
with	  many	  RyR1	  disorders	  are	  much	  needed.	  	  8 
The	  aim	  of	   this	   review	   is	   to	   summarize	   the	  current	  understanding	  of	  RyR1	  structure	  and	  9 
function	   and,	   in	   particular,	   the	   domains	   that	   mediate	   RyR1-­‐protein	   and	   RyR1-­‐ion	   interactions,	  10 
which	  finely	  regulate	  channel	  function.	  The	  interactions	  of	  RyR1	  with	  a	  host	  of	  modulators,	  such	  as	  11 
the	  dihydropyridine	  receptor	  (DHPR),	  FKBP12,	  homer,	  calmodulin,	  S100A1,	  and	  calcium	  have	  been	  12 
well	   studied	  and	  are	  summarized	   in	  Tables	  1	  and	  2	  and	  Figure	  1.	  By	  comparing	   this	   information	  13 
with	  recently	  reported	  recessive	  mutations,	  it	  can	  be	  seen	  that	  many	  of	  these	  mutations	  fall	  within	  14 
RyR1	  protein	  binding	  domains	  ,	  leading	  to	  the	  hypothesis	  that	  abnormal	  RyR1-­‐protein	  interactions	  15 
may	  be	  an	  underlying	  cause	  of	  ryanodine	  receptor	  malfunction	  and	  disease	  (Table	  3).	  16 
	  17 
Structure	  of	  the	  ryanodine	  receptor	  18 
	  19 
The	   ryanodine	   receptor	   is	   the	   largest	   known	   ion	   channel	   and	   forms	   a	   homotetrameric	  20 
structure	   of	   approximately	   2.3	  MDa.	   Each	   565-­‐kDa	  monomeric	   subunit	   consists	   of	   5038	   amino	  21 
acids.	   Approximately	   four-­‐fifths	   of	   the	   channel	   is	  made	   up	   of	   the	   large	   N-­‐terminal	   cytoplasmic	  22 
domain,	  which	  contains	  binding	  sites	  for	  a	  number	  of	  modulators.	  The	  C-­‐terminal	  region	  contains	  23 
the	   transmembrane	   domains	   and	   ion-­‐conducting	   pore.	   RyR1	   is	   characterized	   by	   a	   very	   large-­‐24 
conductance	   with	   moderate	   selectivity	   for	   divalent	   cations	   over	   monovalent	   cations	   [5].	   The	  25 
selectivity	   filter	   contains	   a	   widely	   conserved	   sequence	   (Gly-­‐X-­‐Arg-­‐X-­‐Gly3-­‐X-­‐Gly-­‐Asp)	   found	   in	  26 
several	   different	   cation	   channels,	   including	   potassium	   channels	   and	   IP3Rs.	   Aspartate	   4900	   and	  27 
glycine	   within	   the	   RyR1	  motif	   4895Gly3-­‐Ile-­‐Gly-­‐Asp	   are	   particularly	   important	   for	   ion	   selectivity	  28 
(unless	  otherwise	  indicated	  all	  amino	  acid	  numbers	  refer	  to	  the	  human	  sequence)[6,	  7].	  Figure	  2	  29 
illustrates	   the	   overall	   structural	   information	   of	   the	   RyR1,	   including	   the	   distinct	   cytoplasmic	   and	  30 







Interdomain	  Interactions	  1 
Cryo-­‐electron	  microscopy	   (cryo-­‐EM)	   studies	   indicate	   that	   the	  RyR	  undergoes	  widespread	  2 
long-­‐range	   conformational	   changes	   during	   the	   transition	   from	   closed	   to	   open	   states	   and	   that	  3 
binding	  of	  various	  modulators	  increases	  the	  probability	  of	  the	  ‘on’	  or	  ‘off’	  state	  [10-­‐12].	  A	  domain-­‐4 
switch	  hypothesis	  has	  been	  proposed	  to	  explain	  the	  transition	  between	  ‘on’	  and	  ‘off’	  states	  [13],	  5 
whereby	  several	  subdomains	  throughout	  the	  MH/CCD	  hotspots	  N-­‐terminal	  domain	  1	  (amino	  acids	  6 
35-­‐614)	  and	   the	  central	  domain	  2	   (amino	  acids	  2163-­‐2458)	   interact	   to	   stabilize	   the	  basal	   closed	  7 
conformational	   state	   (Figure	   3).	   Upon	   activation,	   the	   interdomain	   interactions	   are	   disrupted,	  8 
leading	  to	  a	  conformational	  change	  in	  which	  the	  channel	  ‘opens’.	  Perturbation	  of	  the	  interdomain	  9 
interactions	  with	  a	  monoclonal	  antibody	  against	  the	  N-­‐terminal	  domain	  1	  results	  in	  RyR1	  channel	  10 
activation	  [14].	  Interestingly,	  many	  pathogenic	  dominant	  RyR1	  mutations	  associated	  with	  MH	  fall	  11 
within	  MH/CCD	  hotspots	  of	  domains	  1	  and	  2.	  It	  is	  thought	  that	  some	  of	  the	  mutations	  associated	  12 
with	  MH	  weaken	   interdomain	   interactions	  and	  decrease	  the	  energy	  barrier	  required	  for	  channel	  13 
opening,	  resulting	  in	  hypersensitive	  channels	  [15].	  	  14 
	  	  15 
Alternative	  Splicing	  	  16 
Analysis	  of	  rabbit	  RyR1	  cDNA	  reveals	  two	  alternatively	  spliced	  regions	  that	  likely	  modulate	  17 
RyR1	  channel	  properties	  by	  altering	  interdomain	  interactions	  or	  interactions	  with	  other	  proteins.	  18 
Exclusion	  of	  exon	  70	  results	  in	  the	  ASI(-­‐)	  RyR1	  isoform,	  lacking	  five	  residues	  (3481-­‐3485),	  and	  the	  19 
exclusion	  of	  exon	  83	  results	  in	  the	  ASII(-­‐)	  isoform,	  which	  also	  lacks	  five	  residues	  (3865-­‐3870)	  [16].	  20 
There	   is	   conflicting	   data	   on	   whether	   variant	   expression	   is	   tissue-­‐specific	   and	   developmentally	  21 
regulated.	   Zorzato	   and	   colleagues	   reported	   that	   both	   AS	   variants	   are	   found	   in	   fast-­‐	   and	   slow-­‐22 
twitch	  rabbit	  skeletal	  muscles	  irrespective	  of	  their	  developmental	  stage	  [17],	  whereas	  others	  have	  23 
shown	  that	  the	  ASI(-­‐)/ASII(-­‐)	  forms	  predominate	  during	  early	  development	  and	  the	  ASI(+)/ASII(+)	  24 
forms	  predominate	  in	  adulthood	  [16,	  18].	  Abnormal	  overexpression	  of	  the	  ASI(-­‐)	  isoform	  of	  RyR1	  25 
occurs	  in	  myotonic	  dystrophy	  type	  1	  and	  may	  contribute	  to	  muscle	  dysfunction	  [18].	  	  26 
Data	  describing	  the	  functional	  consequences	  of	  expressing	  alternatively	  spliced	  variants	  is	  27 
inconclusive.	  Peptide	   studies	   suggest	   that	   the	  ASI	   region	   together	  with	  an	  adjacent	  basic	  amino	  28 
acid	   sequence	   (the	   combined	   region	   Thr3471-­‐Gly3500)	   are	   involved	   in	   interdomain	   interactions	  29 
that	   stabilize	   the	   closed	   channel	   conformation,	   and	   that	   the	   ASI(-­‐)	   variant	   stabilizes	   the	   closed	  30 
channel	   more	   effectively	   [19].	   Less	   is	   known	   about	   the	   function	   of	   the	   ASII	   region.	   Both	  31 






region	  and	  (ii)	  the	  Arg-­‐Gly-­‐Asp	  (RGD)	  adhesive	  sequence,	  a	  well-­‐established	  protein-­‐binding	  motif;	  1 
[16].	  2 
	  3 
	   Interactions	  with	  Cytoplasmic	  Protein	  Modulators	  4 
RyR1	   interacts	   with	   a	   large	   number	   of	   proteins	   and	   ionic	   modulators.	   Some	   protein	  5 
partners	   have	   been	   investigated	   in	   detail	   and	   their	   corresponding	   binding	   sites	   on	   RyR1	  6 
determined	  with	  confidence	  whereas	  details	  for	  others	  are	  sparse	  and	  uncertain.	  	  7 
	  8 
Dihydropyridine	  Receptor	  (L-­‐type	  Ca2+	  channel)	  9 
In	  skeletal	  muscle,	  there	  is	  a	  regular	  geometric	  arrangement	  of	  RyR1	  and	  DHPR	  channels	  in	  10 
which	   alternate	   RyR1	   channels	   associate	   with	   four	   DHPR	   channels	   [5].	   This	   close	   association	  11 
permits	   direct	   signalling	   between	   the	   DHPRα1.1	   and	   RyR1	   both	   in	   the	   forward	   direction	  12 
(orthograde	  signalling	  in	  which	  DHPR	  activation	  causes	  the	  RyR1	  to	  open)	  and	  retrograde	  signalling	  13 
(whereby	   RyR1	   interactions	   enhance	   current	   through	   the	   DHPR	   channel)	   [20,	   21].	   DHPRs	   are	  14 
composed	  of	  5	  subunits	  The	  α1.1	  subunit	  contains	  the	  voltage	  sensor,	  forms	  the	  pore	  region	  of	  the	  15 
channel,	   and	   is	   believed	   to	   be	   one	   of	   the	   main	   sites	   of	   interaction	   with	   RyR1,	   though	   recent	  16 
research	  supports	  the	  importance	  of	  other	  sites	  [21,	  22].	  Specifically,	  there	  is	  good	  evidence	  that	  17 
the	  α1.1	  II-­‐III	  loop	  (between	  the	  second	  and	  third	  transmembrane	  domains	  of	  the	  α1.1	  subunit)	  and	  18 
the	  β1a	  subunit	  bind	  to	  different	  regions	  of	  RyR1.	  	  19 
Although	   experiments	   using	   RyR1/RyR2	   chimeras	   and	   RyR1	   peptide	   fragments	   have	  20 
sometimes	  yielded	  contrasting	  results	  [21,	  23-­‐27],	  current	  evidence	  implicates	  the	  SPRY2	  domain,	  21 
located	   in	   the	   N-­‐terminal	   cytoplasmic	   region	   of	   RyR1.	   SPRY	   domains	   are	   protein-­‐protein	  22 
interaction	   motifs	   defined	   by	   a	   characteristic	   pattern	   of	   β-­‐sheets.	   The	   RyR1	   isoform	   has	   three	  23 
highly	   conserved	   SPRY	   domains	   (Table	   2).	   Interestingly,	   cryo-­‐EM	  mapping	   of	   the	   SPRY2	   domain	  24 
reveals	   that	   its	   location	  on	  the	  RyR1	  overlaps	  with	   the	  previously	  proposed	  positioning	  of	  DHPR	  25 
[28].	  In	  vitro	  studies	  indicate	  that	  the	  SPRY2	  region	  binds	  the	  DHPR	  α1.1	  II-­‐III	  loop	  [27,	  29]	  and	  may	  26 
also	  participate	  in	  an	  interdomain	  interaction	  within	  RyR1	  [19],	  binding	  to	  the	  broader	  ASI	  region	  27 
via	  the	  positive	  amino	  acid	  cluster	  Lys3495-­‐Arg3502,	  which	   is	  homologous	  to	  a	  similar	  sequence	  28 
on	  the	  II-­‐III	  loop	  of	  the	  DHPR	  α1.1	  subunit.	  The	  physiologic	  importance	  of	  this	  SPRY2/ASI	  interaction	  29 
is	  currently	  uncertain,	  as	  are	  the	  roles	  of	  the	  SPRY1	  and	  SPRY3	  domains.	  30 
Aside	   from	  the	  α1.1	   subunit,	   there	   is	  good	  evidence	  that	  RyR1	  also	  directly	   interacts	  with	  31 






positively	   charged	   motif	   Lys(3495)-­‐Lys-­‐Lys-­‐Arg-­‐Arg-­‐Gly-­‐Asp-­‐Arg(3502)	   [30].	   The	   β1a	   subunit	   may	  1 
play	  a	  dual	   role	   in	   augmenting	  EC	   coupling,	  both	  by	  activating	  RyR1	  during	  EC	   coupling,	   and	  by	  2 
targeting	   the	   DHPR	   to	   precisely	   aligned	   tetrad	   arrays	   on	   the	   t-­‐tubules	   that	   oppose	   the	   RyR1	  3 
complex	  (reviewed	  in	  [31]).	  4 
Early	  studies	  implicated	  other	  RyR1	  regions	  in	  DHPR	  interactions	  but	  the	  domains	  are	  large	  5 
and	   their	   importance	   is	   uncertain.	   The	   second	   of	   three	   divergent	   regions	   (D1-­‐D3),	   so	   named	  6 
because	  the	  sequences	  represent	  areas	  of	  variance	  between	  RyR	  isoforms,	  has	  been	  proposed	  as	  a	  7 
DHPR	  binding	  site	  because	  the	  presence	  of	  residues	  1272-­‐1455	  (region	  D2)	  rescues	  skeletal-­‐type	  8 
EC	   coupling	   [21,	   32,	   33],	  whereas	   deletion	  of	   this	   region	   abolished	   this	   coupling	   [34];	   however,	  9 
other	   studies	   dispute	   this	   finding	   [35].	   In	   addition,	   D2	   has	   been	   shown	   to	   be	   critical	   in	   the	  10 
formation	  of	  DHPR	  tetrads	  [21].	  Experiments	  using	  chimeric	  RyR	  containing	  segments	  of	  different	  11 
isoforms	   (ie:	   RyR1/RyR2	   or	   RyR1/RyR3	   chimera)	   suggest	   that	   RyR1	   residues	   1837–2168	   (rabbit	  12 
cDNA),	   contribute	   to	   both	   EC	   coupling	   and	   calcium	   release	   and	   residues	   2659-­‐3720	   may	   be	  13 
important	  in	  retrograde	  signalling	  [25,	  35].	  14 
	  15 
Calmodulin	  (CaM)	  16 
Calmodulin	   is	   a	   ubiquitously	   expressed,	   highly-­‐conserved,	   17-­‐kDa	   protein	   that	   binds	   the	  17 
cytoplasmic	   surface	   of	   the	   ryanodine	   receptor	   and	  modulates	   its	   activity	   in	   a	   complex	  manner.	  18 
Four	  calmodulin	  molecules	  bind	  per	  RyR	  subunit.	  Calmodulin	  differentially	  regulates	  RyR1	  activity	  19 
depending	  on	  whether	  or	  not	  it	  has	  Ca2+	  bound.	  In	  its	  Ca2+-­‐free	  state	  (apoCaM),	  it	  is	  a	  weak	  partial	  20 
agonist	   whereas	   the	   Ca2+-­‐bound	   form	   (CaCaM)	   is	   a	   stronger	   antagonist	   of	   RyR	   calcium	   release	  21 
[36].	   Thus,	   calmodulin	   likely	   acts	   as	   a	   cytoplasmic	   calcium	   sensor	   for	   RyR.	   It	   may	   also	   affect	  22 
channel	  activity	  by	  influencing	  binding	  to	  DHPR	  (which	  binds	  RyR1	  in	  close	  spatial	  proximity)	  or	  by	  23 
affecting	  RyR1	  interdomain	  interactions	  [37,	  38].	  	  24 
Calmodulin	   binding	   sites	   on	   RyR1	   have	   been	   extensively	   researched	   and	   although	   a	  25 
number	  of	  different	   sequences	  have	  been	  proposed	  based	  on	   the	  experimental	  protocols	  used,	  26 
there	  is	  some	  consensus	  regarding	  the	  importance	  of	  particular	  sequences	  (Figures	  1	  and	  2,	  Table	  27 
2).	   Although	   apoCaM	   and	   CaCaM	   bind	   to	   distinct	   domains	   of	   RyR1,	   some	   studies	   show	   that	  28 
residues	  3614-­‐3643	  and	  2937-­‐3225,	  among	  others,	  bind	  both	  forms	  of	  calmodulin	  [39-­‐42].	  There	  is	  29 
evidence	   that	   CaCaM	  binds	   residues	   3553-­‐3662	   and	   4303-­‐4431	   [40,	   41].	  More	   recent	   data	   also	  30 
suggests	  that	  the	  N-­‐terminus	  of	  calmodulin	  interacts	  with	  sequence	  1975-­‐1999	  [43].	  Interestingly,	  31 






RyR1	   structure	   which	   would	   make	   it	   feasible	   for	   one	   CaM	   molecule	   to	   bind	   both	   sites	  1 
simultaneously	  [43].	  	  2 
	  3 
S100A1	  4 
Like	  calmodulin,	  the	  S100	  proteins	  are	  cytoplasmic	  calcium-­‐binding	  proteins	  containing	  two	  5 
EF-­‐hand	  motifs.	  S100A1	  is	  one	  of	  at	  least	  21	  different	  S100	  isoforms	  expressed	  in	  humans,	  and	  is	  6 
most	  highly	   expressed	   in	   cardiac	   and	   skeletal	  muscle	  where	   it	   regulates	   SR	   calcium	   release	   and	  7 
mitochondrial	  function.	  There	  is	  reasonable	  consensus	  regarding	  the	  S100A1	  binding	  domains	  on	  8 
RyR1	  (Figure	  1	  and	  Table	  2).	  Competition	  assays	  using	  CaCaM	  and	  binding	  experiments	  with	  RyR1	  9 
peptides	  defined	  residues	  3616-­‐3627	  as	  the	  Ca2+-­‐S100A1	  binding	  site	  and	  show	  that	  Ca2+-­‐S100A1	  10 
likely	  competes	  with	  CaCaM	  for	  this	  binding	  domain	  [44].	  This	  finding	  is	  not	  surprising,	  as	  S100A1	  11 
proteins	   and	   calmodulin	   bind	   similar	   structural	   motifs	   in	   other	   proteins.	   The	   physiological	  12 
consequence	  of	  the	  competitive	  binding	  of	  S100A1	  and	  calmodulin	  to	  RyR	  is	  not	  well	  understood.	  	  13 
Physiologically	  relevant	  concentrations	  of	  S100A1	  can	  activate	  RyR1	  in	  vitro.	  When	  applied	  14 
to	  purified	  RyR1	   channels	   reconstituted	   in	   lipid	  bilayers,	   S100A1	  enhances	   the	  normalized	  open	  15 
probability	   of	   RyR1	   at	   nM	   calcium	   concentrations	   [45].	   S100A1	   -­‐/-­‐	   knockout	   mice	   and	   mice	  16 
containing	  a	  mutation	  in	  the	  S100A1	  binding	  domain	  on	  RyR1	  exhibit	  reduced	  SR	  calcium	  release,	  17 
reduced	   global	   cytoplasmic	   calcium	   transients,	   and	   reduced	   force	   generation	   [46-­‐48].	   Further	  18 
experiments	  suggested	  that	   the	  S100A1	  protein	   is	   important	   in	  activating	  RyR1	   in	   response	  to	  a	  19 
single	  action	  potential	  [47,	  48].	  With	  repetitive	  action	  potentials,	  S100/CaM	  binding	  may	  have	  an	  20 
inhibitory	   effect	   because	  mouse	  muscles	   carrying	   a	  mutation	   that	   eliminates	   S100/CaM	  binding	  21 
showed	  increased	  SR	  calcium	  release	  when	  stimulated	  at	  100	  Hz	  [48].	  22 
In	  addition	  to	  residues	  3616-­‐3627,	  initial	  studies	  that	  measured	  the	  ability	  of	  digoxigenin-­‐23 
labelled	  S100A1	  to	  bind	  RyR1	  found	  evidence	  for	  three	  other	  binding	  regions	  (amino	  acids	  1861-­‐24 
2155,	  3773-­‐3873,	  and	  4426-­‐4622)	  [45].	  	  25 
	  26 
FKBP12	  (also	  known	  as	  FK506BP,	  calstabin)	  27 
The	   FK506-­‐binding	   proteins	   (FKBPs)	   are	   immunophilins,	   a	   family	   of	   highly	   conserved	  28 
proteins	  that	  bind	  immunosuppressive	  drugs,	  such	  as	  FK506	  (tacrolimus).	  FKBPs	  are	  expressed	  in	  29 
most	  tissues	  and	  are	  involved	  in	  a	  variety	  of	  cellular	  processes	  including	  protein	  folding,	  receptor	  30 
signalling,	  and	  transcription.	  Two	  isoforms,	  FKBP12	  and	  FKBP12.6	  (also	  known	  as	  calstabin	  1	  and	  2,	  31 






different	   binding	   affinities	   and	   patterns	   of	   tissue	   expression.	   Specifically,	   FKBP12	   is	   the	  1 
predominant	  isoform	  expressed	  in	  skeletal	  muscle	  [49],	  whereas	  FKBP12.6	  co-­‐purifies	  with	  RyR2	  in	  2 
the	  heart.	  3 
In	  normal	  skeletal	  muscle,	  FKBP12	  binds	  to	  the	  cytoplasmic	  side	  of	  RyR	  with	  high	  affinity	  4 
and	  stabilizes	  the	  closed	  conformation.	  Experiments	  using	  immunosuppressive	  drugs	  that	  disrupt	  5 
FKBP12	  binding	   to	  RyR	  and	  FKBP-­‐deficient	  mice	  have	   shown	   that	   loss	  of	  FKBP	  binding	   increases	  6 
the	  open	  probability	  of	   the	  ryanodine	  receptor	  and	   induces	   the	  appearance	  of	  sub-­‐conductance	  7 
states	  of	  the	  channel	  [50,	  51].	  In	  addition	  to	  inhibiting	  RyR,	  FKBP12	  likely	  influences	  EC	  coupling	  by	  8 
modifying	  orthograde	  signalling	  and	  possibly	   retrograde	  signalling	  between	  RyR1	  and	  DHPR	   [52-­‐9 
54].	   FKBP12	   has	   also	   been	   implicated	   in	   coordinating	   gating	   between	   adjacent	   RyR	  molecules,	  10 
which	   results	   in	  neighbouring	   channels	  opening	   simultaneously	   in	   response	   to	  a	   voltage	   change	  11 
[55].	  12 
Four	   FKBP12	   molecules	   can	   bind	   to	   one	   ryanodine	   receptor	   tetramer	   and	   three-­‐13 
dimensional	  cryo-­‐EM	  difference	  mapping	  and	  FRET	  studies	  have	  revealed	  that	  the	  FKBP12	  binding	  14 
site	  is	  close	  to	  the	  clamp	  domain	  [56,	  57].	  A	  study	  that	  mapped	  four	  particular	  mutations	  (human	  15 
residues	  Glu160,	  Arg163,	  Arg401,	  and	  Ile403)	  known	  to	  cause	  malignant	  hyperthermia	  and	  central	  16 
core	  disease	  onto	  the	  cryo-­‐EM	  RyR1	  structure	  suggest	  that	  the	  mutations	  may	  reside	  within	  the	  17 
FKBP12	   binding	   region	   [58],	   but	   this	   has	   not	   been	   experimentally	   confirmed.	   Several	   lines	   of	  18 
evidence	  implicate	  residues	  2458-­‐2468	  as	  an	  important	  FKBP12	  binding	  site	  on	  RyR1	  with	  amino	  19 
acid	  2461	  being	  particularly	  important	  [53].	  20 
	  21 
Interactions	  with	  SR	  Luminal	  Proteins	  	  22 
	  23 
The	   ryanodine	   receptor	   is	  also	  modulated	  by	  proteins	   that	   reside	   in	   the	  SR	   lumen,	  primarily	  24 
triadin,	  junctin	  and	  calsequestrin	  (CSQ),	  which	  likely	  function	  in	  a	  coordinated	  manner.	  25 
	  26 
Triadin	  and	  Junctin	  27 
Triadin	   and	   junctin	   are	   two	   SR	   luminal	   proteins	   that	   interact	   with	   RyR	   to	   regulate	   its	  28 
function.	   Both	   are	   integral	   SR	   membrane	   proteins	   with	   similar	   features,	   such	   as	   a	   short	  29 
cytoplasmic	   N-­‐terminal	   tail,	   a	   single	   transmembrane	   domain,	   and	   a	   longer	   C-­‐terminal	   tail	   that	  30 
extends	   into	   the	   SR	   lumen.	   The	   C-­‐terminal	   tails	   of	   both	   proteins	   contain	   multiple	   clusters	   of	  31 






well	  [59,	  60].	  Recent	  research	  emphasizes	  the	  importance	  of	  RyR2-­‐triadin	  interactions	  for	  channel	  1 
function	   in	   the	   heart.	   In	   skeletal	  muscle,	   triadin	   knockdown	   affects	   voltage-­‐dependent	   calcium	  2 
release	  and	  reduces	  muscle	  function	  [61,	  62],	  whereas	  disruption	  of	  triadin	  binding	  reduces	  both	  3 
voltage-­‐	   and	   ligand-­‐gated	   SR	   calcium	   release,	   suggesting	   that	   triadin	  may	  play	   a	   role	   in	   skeletal	  4 
muscle	   EC	   coupling	   [63].	   The	   primary	   triadin	   binding	   site	   on	   RyR1	   has	   determined	   by	   in	   vitro	  5 
binding	   and	   site-­‐directed	  mutagenesis	   is	   the	   second	   intraluminal	   loop	   of	   RyR1	   (residues	   4861-­‐6 
4918).	   In	   particular,	   three	   acidic	   residues	   (Asp4879,	   Asp4908,	   and	   Glu4909)	   are	   particularly	  7 
important	  [60].	  The	  second	  intraluminal	  loop	  may	  also	  contain	  the	  pore	  and	  selectivity	  filter	  of	  the	  8 
calcium	   channel.	   A	   number	   of	   dominant	   RYR1	   mutations	   found	   in	   patients	   with	   central	   core	  9 
disease	  fall	  within	  the	  triadin	  binding	  domain,	  but	  their	  effects	  on	  protein-­‐protein	  interaction	  have	  10 
not	  been	  investigated.	  11 
It	   has	  been	   suggested	   that	   junctin	  may	  be	   the	  main	  protein	  mediator	  between	  CSQ	  and	  12 
RyR	  [64].	  Knockdown	  of	  junctin	  in	  myotubes	  reduces	  both	  depolarization-­‐induced	  SR	  Ca2+	  release	  13 
and	  reduced	  SR	  Ca2+	  stores	   [61],	  possibly	  by	  disrupting	  the	  signalling	  complex	  between	  CSQ	  and	  14 
RyR.	  The	   role	  of	   junctin	   in	  maintaining	  SR	  Ca2+	   stores	  as	  well	  as	   its	  binding	  site	  on	  RyR1	   remain	  15 
uncertain.	  	  16 
	  17 
Calsequestrin	  (CSQ)	  18 
CSQ	   is	   the	   primary	   calcium-­‐binding	   protein	   in	   the	   SR	   lumen	   and	   its	   high-­‐capacity/low-­‐19 
affinity	  binding	  properties	  for	  calcium	  ions	  make	  it	  a	  highly	  effective	  calcium	  storage	  protein,	  with	  20 
around	  40-­‐50	  calcium	  ions	  bound	  per	  CSQ	  molecule	  in	  skeletal	  muscle	  [65].	  Though	  in	  vitro	  studies	  21 
demonstrate	  the	  ability	  of	  CSQ	  to	  bind	  directly	  to	  RyR1,	  it	  is	  uncertain	  whether	  this	  occurs	  in	  vivo	  22 
or	  if	  CSQ	  interacts	  with	  RyR	  through	  triadin/junctin	  interactions	  [66].	  Purified	  RyR	  channels	  freed	  23 
from	   triadin	  and	   junctin	  were	  not	   inhibited	   in	   response	   to	  exogenous	  CSQ,	   suggesting	   that	  CSQ	  24 
does	  not	  bind	  directly	  to	  RyR1	  [67].	  	  25 
	  26 
Other	  Potential	  Protein	  Modulators	  27 
	   A	  number	  of	  other	  potential	  protein	  modulators	  of	  the	  RyR1	  channel	  have	  been	  discovered	  28 
but	  the	  specific	  RyR1	  binding	  sites	  are	  currently	  undefined	  for	  these	  proteins.	  29 
	  30 






CHERP	   is	   a	   recently	   identified	   integral	   SR/ER	  membrane	   protein	   shown	   to	   interact	   with	  1 
RyR1	   through	   pull-­‐down	   and	   co-­‐localization	   studies	   [68].	   CHERP	   participates	   in	   cytosolic	   Ca2+	  2 
cycling	   within	   cells	   and	   affects	   diverse	   cellular	   processes,	   such	   as	   DNA	   synthesis,	   growth	   and	  3 
proliferation	  [69].	  siRNA-­‐mediated	  suppression	  of	  CHERP	  expression	   in	  HEK-­‐293	  cells	  transfected	  4 
with	  the	  full-­‐length	  RyR1	  resulted	  in	  decreased	  calcium	  flux	  through	  the	  ryanodine	  receptor	  [68]	  5 
but	  further	  work	  is	  required	  to	  confirm	  that	  CHERP	  is	  a	  direct	  binding	  partner	  of	  RyR1	  in	  vivo	  and	  6 
to	  clarify	  its	  physiological	  role.	  	  7 
	  8 
Homer/Ves1	  9 
Homer	  proteins	  are	  high-­‐affinity	  ligands	  that	  modify	  RyR	  channel	  function.	  Within	  neurons	  10 
and	  other	  tissues,	  homer	  proteins	  are	  important	  anchoring	  or	  adaptor	  proteins	  that	  facilitate	  the	  11 
formation	   of	   multimeric	   protein	   complexes	   [70].	   Homer	   may	   play	   a	   similar	   role	   in	   the	   SR	   by	  12 
stabilizing	   interactions	  between	  RyR1	  and	  possibly	  DHPR.	  Different	  homer	   isoforms	   (e.g.	   1b,	   1c,	  13 
and	  2b)	  activate	  RyR1	  in	  single-­‐channel	  experiments,	  induce	  calcium	  release	  from	  SR	  vesicles,	  and	  14 
increase	  the	   frequency	  of	  calcium	  sparks	   from	  permeabilized	  skeletal	  muscle	   fibers	   (reviewed	   in	  15 
[71]).	  16 
Homer	   proteins	   contain	   EVH1	   domains	   that	   facilitate	   binding	   to	   proline-­‐rich	   consensus	  17 
sequences	  on	  target	  proteins,	  defined	  by	  Pro-­‐Pro-­‐X-­‐X-­‐ɸ	  (where	  X=any	  amino	  acid	  and	  ɸ=aromatic	  18 
residue),	   flanked	  by	  charged	  residues	  [71].	  There	  are	  many	  homer	  consensus	  sequences	   in	  RyR1	  19 
(Figure	  1	  and	  Table	  2).	  	  20 
	  21 
Selenoprotein	  22 
Selenoproteins	   contain	   a	   selenocysteine	   residue	   (a	   modified	   cysteine	   residue	   where	  23 
selenium	  replaces	   the	   sulphur	  moity),	  and	  are	   implicated	   in	  diverse	  processes	   that	   capitalize	  on	  24 
the	  high	  redox	  potential	  of	  the	  selenium	  ion.	  One	  study	  demonstrated	  that	  selenium	  compounds	  25 
induce	  calcium	  release	   from	  SR	  vesicles,	  affect	   ryanodine	  binding	  at	  varying	  concentrations,	  and	  26 
stimulate	  or	  inhibit	  RyR	  by	  binding	  free	  thiols	  within	  the	  protein	  [72].	  Selenoprotein	  N	  (SelN)	  is	  a	  27 
SR	   transmembrane	   protein	   found	   to	   be	   associated	   with	   RyR1	   in	   vivo	   and	   required	   for	   normal	  28 
muscle	  development	  and	  differentiation	  in	  zebrafish	  muscle	  [73].	  When	  SelN	  is	  absent,	  RyR	  loses	  29 
its	  normal	  sensitivity	  to	  redox	  modulation	  [73].	  Mutations	  in	  SEPN1,	  which	  encodes	  SelN,	  cause	  a	  30 
skeletal	   myopathy	   with	   many	   histological	   and	   phenotypic	   similarities	   to	   RYR1-­‐related	   multi-­‐31 






status	   and	   function	   of	   RyR1	   [74].	   It	   has	   not	   yet	   been	   clarified	  whether	   SelN	   and	   RyR1	   interact	  1 
directly	  and,	  if	  they	  do,	  the	  binding	  sites	  that	  are	  involved.	  2 
	  3 
Interactions	  with	  Ions	  and	  Small	  Molecular	  Modulators	  4 
	  5 
	   Aside	   from	  protein	   ligands,	   the	   ryanodine	   receptor	   is	   also	   regulated	   by	   several	   ions	   and	  6 
small	  molecules,	   including	  calcium,	  magnesium,	  and	  ATP.	  Calcium	  and	  magnesium,	   in	  particular,	  7 
likely	  interact	  at	  numerous	  sites	  to	  influence	  channel	  function.	  8 
	  9 
Calcium	  (Ca2+)	  10 
Ca2+	  modulates	  RyR1	   function	  both	  directly	  and	   indirectly	   through	   interactions	  with	  both	  11 
the	   cytoplasmic	   and	   SR	   luminal	   surfaces	   of	   RyR1.	   The	   indirect	   effect	   is	   mediated	   primarily	   by	  12 
calmodulin	  and	  CaMKII,	  but	  also	  via	  S100A1,	  triadin,	  junctin,	  and	  calsequestrin	  (discussed	  above).	  13 
The	  direct	  effects	  of	  calcium	  on	  channel	  function	  are	  discussed	  in	  this	  section.	  14 
The	  Ca2+	  concentration	  in	  the	  SR	  lumen	  may	  directly	  modulate	  calcium	  release	  from	  RyR1.	  15 
In	   lipid	  bilayer	   single	  channel	  experiments	  as	   the	  SR	   lumen	  Ca2+	   levels	  are	   increased	   there	   is	  an	  16 
enhanced	  sensitivity	  of	  RyR1	  to	  cytosolic	  agonists,	  such	  as	  caffeine	  and	  ATP	  [75-­‐77].	  However,	   it	  17 
remains	  uncertain	  whether	  there	  are	  specific	  Ca2+-­‐binding	  sites	  on	  the	  SR	  luminal	  face	  of	  RyR1	  or	  18 
whether	  Ca2+	  can	  modulate	  activity	  by	  passing	  through	  the	  channel	  pore	  and	  binding	  to	  sites	  on	  19 
the	  cytoplasmic	  surface.	  Recent	  evidence	  suggests	  the	  presence	  of	  luminal	  sites	  in	  RyR2	  [78,	  79].	  	  20 
RyR1	   activity	   exhibits	   a	   bell-­‐shaped	   dependence	   on	   cytoplasmic	   Ca2+	   arising	   from	   the	  21 
binding	  of	  Ca2+	   to	   two	  distinct	   classes	  of	  binding	  sites:	   low	   [Ca2+]	  bind	   to	  high-­‐affinity	  activation	  22 
sites	  and	  high	  [Ca2+]	  bind	  to	   low-­‐affinity	   inactivation	  sites.	  Evidence	  suggests	  that	  the	  C-­‐terminal	  23 
third	  of	  RyR1	  contains	  several	  important	  high-­‐affinity	  Ca2+-­‐binding	  sites	  [80].	  Polyclonal	  antibodies	  24 
raised	   against	   residues	   4380-­‐4625	   inhibit	   Ca2+-­‐induced	   calcium	   release	   from	   isolated	   SR	   [81].	  25 
Overlay	   studies	   and	   site-­‐directed	   polyclonal	   antibodies	   indicate	   Ca2+-­‐binding	   residues	   at	   4245-­‐26 
4378	   and	   4479-­‐4515	   [82].	   A	   negatively	   charged	   Pro-­‐Glu	   repeat	   sequence	   (PEPEPEPEPEPE)	   at	  27 
residues	   4490-­‐4502	   is	   likely	   the	   critical	   Ca2+-­‐binding	   domain	   in	   this	   region	   because	   antibodies	  28 
raised	   against	   this	   sequence	   inhibit	   Ca2+-­‐dependent	   RyR1	   activation	   [83].	   Site-­‐directed	  29 
mutagenesis	   provides	   evidence	   for	   physiologically-­‐important	   calcium-­‐binding	   at	   human	   RyR1	  30 
residue	  Glu4031	  (equivalent	  to	  rabbit	  RyR3	  residue	  Asp3885)	  [84].	  The	  RyR1	  likely	  has	  other	  high-­‐31 






Less	   is	   known	   about	   the	   low-­‐affinity	   Ca2+-­‐inactivation	   sites	   and	   the	   available	   data	   is	  1 
contradictory.	  A	  truncated	  RyR	  channel	  lacking	  residues	  1-­‐3660	  failed	  to	  close	  at	  high	  [Ca2+],	  which	  2 
may	   indicate	   that	   Ca2+	   inactivation	   sites	   are	   located	   in	   the	   N-­‐terminal	   foot	   of	   the	   protein	   [85];	  3 
however,	  the	  absence	  of	  such	  a	  large	  portion	  of	  the	  protein	  likely	  affects	  the	  overall	  structure	  of	  4 
the	   RyR1.	   Other	   studies	   suggest	   the	   importance	   of	   the	   C-­‐terminus	   for	   inactivating	   Ca2+-­‐binding	  5 
sites.	  Indeed,	  RyR1/RyR2	  chimeras	  containing	  an	  RyR2	  C-­‐terminal	  domain	  show	  reduced	  inhibition	  6 
of	  the	  channel	  at	  elevated	  Ca2+	  levels,	  suggesting	  that	  the	  C-­‐terminal	  region	  (residues	  3726-­‐5038)	  7 
contains	   important	   Ca2+-­‐inactivation	   sites	   [86].	   Specifically,	   mutation	   of	   a	   putative	   EF	   hand-­‐8 
homology	   region	   (4080-­‐4091)	   greatly	   enhances	   channel	   activity,	   supporting	   the	   idea	   that	   this	  9 
region	   is	   an	   important	   calcium-­‐inactivation	   site	   [87].	   Other	   possible	   Ca2+-­‐inactivation	   sites	   have	  10 
been	  identified	  throughout	  the	  RyR1	  protein	  sequence	  such	  as	  between	  residues	  4063-­‐4209	  [88].	  11 
	  12 
Magnesium	  13 
The	  effect	  of	  magnesium	  on	  channel	  function	  is	   intimately	   linked	  to	  Ca2+	   levels.	  Based	  on	  14 
single	  channel	  experiments	  and	  studies	  of	  calcium	  release	  from	  SR	  vesicles,	  there	  is	  good	  evidence	  15 
that	   Mg2+	   competes	   with	   Ca2+	   for	   the	   high-­‐affinity	   Ca2+-­‐activation	   binding	   sites	   and	   prevents	  16 
channel	  activation.	  A	   second	   likely	  mechanism	   involves	   the	   low-­‐affinity	  Ca2+-­‐inactivation	  binding	  17 
sites,	  which	  are	  less-­‐selective	  to	  divalent	  ions	  and	  permit	  Mg2+	  to	  inhibit	  channel	  function	  [89].	  It	  18 
was	  recently	  shown	  that	  the	  relative	  concentrations	  of	  SR	  luminal	  Ca2+	  and	  Mg2+	  play	  an	  important	  19 
role	  in	  determining	  the	  unitary	  calcium	  current	  amplitude	  through	  the	  RyR	  pore.	  	  As	  the	  SR	  Mg2+	  20 
load	   increases	   the	  open	  probability	  decreases,	   leading	   to	   lower	   intracellular	   calcium	   levels	   [90].	  21 
The	  current	  model	  predicts	  that	  the	  Mg2+	  binding	  sites	  on	  RyR1	  overlap	  with	  those	  for	  Ca2+.	  22 
	  23 
ATP	  24 
Overall,	   ATP	   is	   an	   activator	   of	   RyR1	   but	   the	   strength	   of	   its	   effects	   depends	   on	   the	  25 
concentration	   of	   Ca2+,	   Mg2+	   and	   other	   exogenous	   modulators	   that	   may	   modify	   the	   number	   of	  26 
accessible	  ATP	  binding	  sites	  [91,	  92].	  In	  [3H]ryanodine	  binding	  and	  single	  channel	  measurements,	  27 
ATP	  only	  minimally	  activates	  the	  channel	  at	   low	  Ca2+	  concentrations	  and	  µM	  Ca2+	   is	  required	  for	  28 
maximal	  activation	  of	  RyR	  by	  ATP	   [91].	  Other	  adenine	  nucleotides,	   such	  as	  AMP	  and	  adenosine,	  29 






Based	  on	  a	  proposed	  nucleotide	  binding	  motif,	  there	  are	  several	  possible	  ATP	  binding	  sites	  1 
on	  RyR1.	  Photoaffinity	  labelling	  has	  confirmed	  possible	  ATP-­‐binding	  regions	  [93];	  however,	  further	  2 
resolution	  of	  these	  segments	  is	  required.	  3 
	  4 
NADH	  and	  NADH	  Oxidase	  5 
Cyclic	   adenosine	   diphosphate	   (cADP)	   ribose	   and	   nicotinamide-­‐adenine	   dinucleotides	  6 
(NAD+/NADH)	   modulate	   RyR	   function	   in	   an	   isoform	   specific	   way.	   cADP	   ribose	   increases	   Ca2+	  7 
transients	  through	  RyR1,	  either	  by	  acting	  directly	  on	  the	  receptor	  or	  by	  affecting	  ancillary	  protein	  8 
binding	   partners	   [94].	   NAD	   species	   (NAD+/NADH,	   NADP+/NADPH)	   are	   redox-­‐based	   signalling	  9 
molecules	  affecting	  a	  wide	  range	  of	  biological	  pathways.	  Direct	  redox	  modulation	  of	  reactive	  thiol	  10 
groups	  on	  the	  RyR	  has	  been	  described	  (see	  “Redox	  Modulation”	  section),	  but	  the	  mechanism	  by	  11 
which	   NAD	   species	   affect	   RyR	   channel	   function	   may	   be	   isoform-­‐specific.	   Some	   studies	  12 
demonstrate	  that	  both	  NAD+	  and	  NADH	  activate	  RyR1	  [95,	  96],	  while	  others	  found	  that	  NADH	  has	  13 
minimal	   effects	   [97].	   NAD	   species	   may	   influence	   RyR1	   activity	   through	   several	   mechanisms.	  14 
NAD+/NADH	   may	   interact	   directly	   with	   RyR1	   at	   ATP-­‐binding	   sites	   due	   to	   structural	   similarities	  15 
between	   these	   two	   molecules	   [95].	   An	   NADH-­‐dependent	   oxidase	   (NOX)	   present	   in	   the	   SR	  16 
membrane	  interacts	  with	  RyR1	  and	  reduces	  reduced	  oxygen	  to	  superoxide,	  which	  in	  turn	  activates	  17 
RyR1	  [96].	  In	  addition,	  a	  potential	  oxidoreductase-­‐like	  domain	  is	  present	  in	  the	  N-­‐terminus	  of	  RyR1	  18 
(residues	  40-­‐419)	  that	  may	  bind	  NAD+	  and	  act	  as	  a	  redox	  sensor	  discussed	  in	  [58].	  19 
	  20 
Posttranslational	  Modification	  of	  the	  Ryanodine	  Receptor	  21 
	  22 
	   The	   ryanodine	   receptor	   undergoes	   posttranslational	   modification	   through	   a	   range	   of	  23 
physiologic	  processes	   such	  as	  phosphorylation,	  oxidation,	  and	  nitrosylation,	  all	  of	  which	  may	  be	  24 
elicited	  by	   stress-­‐dependent	   signalling	   pathways	   [98].	   The	   effects	   of	   these	  modifications	   on	   the	  25 
ryanodine	  receptor	  are	  complex	  and	  controversial,	  but	  recent	  studies	  are	  beginning	  to	  clarify	  this	  26 
field.	  27 
	  28 
Kinases	  and	  Phosphatases	  29 
The	   ryanodine	   receptor	   can	   be	   phosphorylated	   and	   dephosphorylated	   by	   a	   range	   of	  30 
kinases	   and	   phosphatases	   such	   as	   protein	   kinase	   A	   (PKA),	   Ca2+/calmodulin-­‐dependent	   protein	  31 






body	  of	  data	  relates	  to	  RyR2	  in	  cardiac	  muscle.	  Most	  studies	  indicate	  that	  phosphorylation	  by	  PKA,	  1 
which	   is	   activated	   by	   β-­‐adrenergic	   signals,	   activates	   RyR2	   and	   Ca2+	   release,	   thereby	   inducing	   a	  2 
positive	  inotropic	  effect	  on	  the	  heart	  [103].	  Initial	  studies	  in	  skeletal	  muscle	  found	  variable	  effects	  3 
of	  phosphorylation	  on	  channel	  activity,	  but	  there	  is	  an	  emerging	  consensus	  that	  phosphorylation	  4 
by	  PKA	  or	  CAMKII	  activates	  RyR1	  [100,	  104,	  105].	  	  5 
There	   is	   good	   evidence	   that	   interactions	   between	   RyR	   and	   various	   kinases	   and	  6 
phosphatases	  require	  binding	  of	  specific	  targeting	  proteins	  to	  highly	  conserved	  leucine/isoleucine	  7 
zipper	  (LIZ)	  motifs	  located	  on	  RyR	  channels	  [106].	  These	  LIZ	  motifs	  interact	  with	  targeting	  proteins,	  8 
such	  as	  muscle	  A-­‐kinase	  anchoring	  protein	  (mAKAP)	  and	  spinophilin,	  which	  localize	  specific	  kinases	  9 
and	  phosphatases,	  such	  as	  PKA	  and	  protein	  phosphatase	  I	  (PPI)	  respectively,	  to	  the	  RyR.	  Although	  10 
these	  results	  were	  first	  demonstrated	  for	  the	  RyR2	  macromolecular	  complex,	  the	  RyR2	  LIZ	  motifs	  11 
that	  bind	  PKA	  and	  PPI	  are	  highly	  conserved	   in	  RyR1.	  RyR1	  residues	  553-­‐602	  co-­‐precipitated	  with	  12 
PPI	  and	  residues	  3039-­‐3075	  co-­‐precipitated	  with	  PKA	   [106].	  A	  consensus	  sequence	   (Arg-­‐His-­‐Arg-­‐13 
(Val)-­‐Ser-­‐Leu)	   within	   the	   calmodulin	   binding	   domain	   also	   binds	   PKA	   (residues	   3051-­‐3056)	   and	  14 
Ser3055	   is	   the	   likely	   phosphorylation	   target	   [107].	   Ser3055	   phosphorylation	   is	   inhibited	   when	  15 
calmodulin	  binds	  RyR1	  and	  the	  binding	  of	  calmodulin	  is	  inhibited	  by	  Ser3055	  phosphorylation.	  16 
Phosphorylation	   of	   Ser2843	   occurs	   in	   vivo	   and	   there	   are	   several	   further	   potential	  17 
phosphorylation	  consensus	  sites	  in	  RyR1	  that	  require	  confirmation	  (Figure	  1).	  Phosphorylation	  at	  18 
Ser2843	  may	   increase	   the	   sensitivity	   of	   RyR1	   to	   cytoplasmic	   Ca2+	   and	   promote	   release	   of	   FKBP	  19 
from	  RyR1	   thereby	   destabilizing	   the	   closed	   conformation	   [103]	   but	   other	   studies	   challenge	   this	  20 
finding	  [108].	  21 
	  22 
Redox	  Modulation	  23 
It	   is	  well-­‐established	   that	   RyR	   channel	   function	   is	   altered	   by	   reversible	   redox	   processes,	  24 
such	   as	   cysteine	   (disulphide)	   oxidation,	   S-­‐nitrosylation,	   and	   S-­‐glutathionylation.	   Abnormal	  25 
oxidation	  of	  RyR1	  has	  been	  implicated	  in	  several	  disease	  states,	  such	  as	  muscular	  dystrophy	  and	  26 
heart	  failure	  [98,	  109]	  but	  a	  detailed	  understanding	  is	  lacking.	  27 
Reactive	  oxygen	  species	  and	   reactive	  nitrogen	  species	  are	  continuously	  generated	  within	  28 
active	  skeletal	  muscle	  and	  can	  modulate	  muscle	  function.	  RyR1	  is	  a	  major	  cellular	  redox	  sensor	  in	  29 
skeletal	  muscle,	  having	  ~100	  cysteine	  thiol	  groups	  on	  its	  surface.	  Three	  general	  classes	  of	  thiols	  are	  30 
proposed:	  (i)	  most	  are	  likely	  inert	  and	  resist	  oxidation	  during	  normal	  activity;	  (ii)	  6-­‐8	  thiol	  groups	  31 






function	  in	  conditions	  of	  moderate	  oxidative	  stress	  such	  as	  during	  vigorous	  exercise;	  and	  (iii)	  thiols	  1 
that	   can	   be	   oxidized	   by	   extreme	   oxidative	   stress,	   impairing	   RyR	   channel	   function	   [110].	   Some	  2 
redox-­‐active	  cysteines	   in	  RyR1	  are	   located	   in	  calmodulin-­‐	  and	  FKBP12-­‐binding	  regions	  [111],	  and	  3 
changes	   in	   binding	   affinity	   for	   these	   effectors	   is	   one	   way	   that	   the	   oxidative	   environment	  4 
modulates	  RyR1	  function	  [109].	  	  5 
As	   a	   general	   rule,	   oxidizing	   reagents	   activate	   and	   reducing	   reagents	   inhibit	   RyR	   channel	  6 
activity	   [112].	   In	   vitro	   RyR1	  activity	   is	   increased	  by	  many	  oxidizing	   species,	   including	   superoxide	  7 
anion,	  hydrogen	  peroxide,	  hydroxyl	  radicals	  and	  nitric	  oxide	  although	  channel	  function	  is	  inhibited	  8 
in	  extreme	  oxidative	  environments.	  The	  relationships	  between	  redox	  state,	  other	  factors	  such	  as	  9 
membrane	  potential	  or	  the	  concentrations	  of	  RyR1	  protein	  modulators,	  and	  channel	  function	  are	  10 
extremely	  complex	  and	  beyond	  the	  scope	  of	  this	  article.	  11 
There	   is	   little	   consensus	  on	   the	   location	  of	   the	   specific	   cysteine	   residues	   that	   are	   redox-­‐12 
active.	  Cysteine	  residues	  at	  positions	  35,	  314,	  810,	  905,	  1039,	  1302,	  1590,	  2326,	  2363,	  2436,	  2565,	  13 
2606,	  2611,	  3193	  and	  3635	  have	  been	   implicated	   in	  at	   least	  one	   study	   [113,	  114].	  Cys3635	  has	  14 
been	   confirmed	   as	   redox-­‐sensitive	   in	   two	   studies	   and	   has	   been	   implicated	   in	   voltage-­‐gated	   EC	  15 
coupling	  and	  regulation	  of	  calmodulin	  binding	  [43,	  115].	  16 
	  17 
Using	  information	  about	  RyR1	  functional	  domains	  to	  understand	  disease	  pathogenesis	  18 
	  19 
As	  an	  example	  of	  how	  information	  on	  RyR1	  functional	  domains	  can	  be	  used	  to	  investigate	  20 
the	   possible	   disease	   mechanisms,	   we	   have	   analyzed	   a	   range	   of	   myopathy	   cases	   caused	   by	  21 
recessive	  RYR1	  mutations	  (Table	  3).	  Some	  patients	  are	  compound	  heterozygous	  for	  two	  different	  22 
missense	   mutations,	   but	   interestingly,	   over	   half	   of	   patients	   are	   compound	   heterozygous	   for	   a	  23 
missense	   mutation	   and	   a	   ‘null’	   mutation	   (including	   protein-­‐truncation	   mutations	   or	  24 
frameshift/splice-­‐site	   mutations	   that	   disrupt	   the	   reading	   frame).	   Such	   ‘null’	   mutations	   likely	  25 
abolish	  protein	  expression	  from	  that	  allele	  and	  the	  phenotype	  is	  probably	  determined	  primarily	  by	  26 
the	  sequence	  variant	  on	  the	  other	  RYR1	  allele	  (carrying	  the	  missense	  mutation).	  Analysis	  of	  these	  27 
missense	   mutations	   can	   give	   insights	   into	   disease	   pathogenesis.	   For	   example,	   the	   Arg2435Leu	  28 
mutation	  changes	  a	  conserved	  arginine	   residue	   that	   likely	  alters	   the	   redox-­‐sensing	  properties	  of	  29 
Cys2436.	   Three	   mutations,	   His2035Leu,	   Arg3772Gln	   and	   Arg3772Trp	   sit	   within	   or	   immediately	  30 






interactions.	  In	  this	  way,	  in-­‐silico	  analysis	  of	  different	  mutations	  can	  generate	  hypotheses	  that	  can	  1 
inform	  research	  into	  disease	  pathogenesis.	  	  2 
	  3 
VIII.	   Concluding	  Remarks	  4 
	  5 
	   After	  reviewing	  the	  existing	  knowledge	  about	  the	  structure	  of	  RyR1	  and	  the	  relationship	  to	  6 
its	   function,	   it	   is	   clear	   there	   is	  much	   left	   to	   discover.	   For	  most	   parts	   of	   the	   protein,	   it	   remains	  7 
uncertain	  how	  the	  amino	  acid	  sequences	  fold	  to	  form	  the	  tertiary	  protein	  structure	  and	  the	  role	  of	  8 
specific	  residues	   in	  specific	  channel	  functions	   is	  based	  on	  partial	   information.	  Achieving	  a	  crystal	  9 
structure	   for	   the	   full	   tetrameric	   complex	   will	   be	   a	   major	   milestone	   for	   the	   field	   and	   for	  10 
understanding	  the	  molecular	  basis	  of	  various	  channel	  properties.	   It	   is	  also	  clear	  that	  our	  current	  11 
knowledge	   of	   how	   channel	   function	   is	   modulated	   by	   various	   interacting	   proteins	   and	   small	  12 
molecules	   is	   rudimentary.	   Many	   other	   interacting	   proteins	   likely	   remain	   undiscovered	   and	   the	  13 
RyR1	  binding	  sites	  for	  many	  recognized	  interacting	  proteins	  are	  uncertain.	  Advancing	  this	  field	   is	  14 
not	   only	   important	   for	   understanding	   normal	   skeletal	   muscle	   function,	   but	   will	   influence	   the	  15 
treatment	  of	  many	  muscle	  disorders.	  Drugs	  can	  now	  be	  designed	  to	  modulate	  specific	  molecular	  16 
interactions	  and	  the	  potential	  to	  normalize	  RyR1	  function	  using	  small	  molecules	  in	  primary	  RYR1-­‐17 
myopathies	  and	  other	  skeletal	  muscle	  disorders	  is	  great.	  At	  present	  this	  a	  distant	  goal	  but	  we	  hope	  18 
that	  consolidating	  our	  knowledge	  of	  the	  functional	  domains	  of	  RyR1	  is	  a	  useful	  early	  step	  on	  this	  19 
journey.	  We	  also	  hope	   that	   it	  helps	   the	   investigation	  of	   the	  ways	   that	  different	  RYR1	  mutations	  20 
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TEXT	  BOXES	  1 
	  2 
Box	  1.	  RyR1-­‐related	  muscle	  disorders.	  3 
	  4 
Malignant	   hyperthermia	   (MH)	   is	   a	   potentially	   fatal	   pharmacogenetic	   disorder	   in	   which	   a	  5 
hypermetabolic	  state	  is	  evoked	  by	  volatile	  anaesthetics	  or	  depolarizing	  muscle	  agents.	  Symptoms	  6 
include	  hypercapnia,	  metabolic	  acidosis,	  tachycardia,	  generalized	  muscle	  rigidity,	  rhabdomyolysis,	  7 
and	   hyperthermia.	   Most	   MH-­‐susceptible	   individuals	   have	   normal	   muscle	   function	   so	   long	   as	  8 
triggering	  agents	  are	  avoided	  but	  some	   individuals	  with	  congenital	  myopathies	  because	  of	  RYR1	  9 
mutations	   may	   be	   at	   risk	   of	   developing	   an	   MH	   reaction.	   Dantrolene,	   which	   acts	   on	   RyR1,	   is	  10 
currently	  the	  only	  available	  treatment.	  Dominant	  RYR1	  mutations	  are	  the	  leading	  cause	  of	  MH.	  11 
	  12 
Congenital	  myopathies	   are	   uncommon	  muscle	   disorders	   that	   usually	   present	   at	   birth	   or	   during	  13 
infancy	   with	   generalized	   muscle	   weakness	   and	   low	   muscle	   tone.	   	   There	   are	   many	   forms	   of	  14 
congenital	  myopathy,	  each	  defined	  by	  a	  specific	  pattern	  of	  histologic	  abnormalities.	   	  The	  clinical	  15 
severity	   varies.	  Most	   individuals	   with	   congenital	  myopathies	   follow	   a	   stable	   clinical	   course	   and	  16 
current	   medical	   treatment	   is	   based	   on	   supportive	   care.	   	   Patients	   may	   develop	   respiratory	  17 
involvement,	   joint	   contractures,	   distinctive	   weakness	   of	   eye	   movements	   (ophthalmoplegia),	  18 
scoliosis,	  or	  difficulty	   swallowing	   (dysphagia).	   	  Mutations	   in	  RYR1	   are	  an	   important	  cause	  of	   the	  19 
following	  congenital	  myopathies.	  20 
	  21 
§ The	  core	  myopathies	  are	  characterized	  by	  regions	  devoid	  of	  mitochondria	  in	  muscle	  fibers	  22 
that	  appear	  as	  ‘cores’	  on	  oxidative	  stains.	  In	  central	  core	  disease	  (CCD),	  cores	  are	  large	  and	  23 
extend	  longitudinally.	  In	  multi-­‐minicore	  disease	  (MmD)	  the	  cores	  are	  short	  and	  vary	  in	  size	  24 
and	  location.	  25 
	  26 
§ Centronuclear	  myopathy	   (CNM)	   is	   characterized	  by	   the	  presence	  of	  numerous	   internally	  27 
located	  nuclei	  within	  muscle	  fibers.	  28 
	  29 
§ Congenital	   fiber	   type	   disproportion	   (CFTD)	   is	   characterized	   by	   a	   marked	   consistent	  30 
difference	   in	   size	   between	   type	   1	   fibers	   (which	   are	   small)	   and	   type	   2	   fibers	   (which	   are	  31 
large),	  when	  there	  are	  no	  other	  histological	  abnormalities.	  32 
	  33 
	  34 






FIGURE	  LEGENDS	  1 
	  2 
Figure	  1.	  Protein/ion	  binding	  domains	  distributed	  across	  the	  RyR1	  protein	  sequence.	  3 
	  4 
Figure	  2.	  Proposed	  architecture	  of	  RyR1	  based	  on	  cryo-­‐EM	  at	  10	  Å	  resolution.	  Adapted	  from	  [116].	  	  5 
	  6 
Figure	  3.	  Interdomain	  interaction	  within	  RyR1.	  The	  N-­‐terminal	  and	  central	  domains	  interact	  with	  7 
one	  another	  to	  stabilize	  the	  closed	  configuration	  of	  the	  channel.	  When	  this	  interaction	  is	  disrupted	  8 
and	  “unzipped,”	  either	  by	  means	  of	  a	  competing	  synthetic	  domain	  peptide,	  pathogenic	  mutation,	  9 
or	  physiologic	  activation,	  the	  channel	  becomes	  destabilized	  and	  allows	  the	  passage	  of	  calcium	  ions	  10 
through	  the	  pore.	  aa	  =	  amino	  acids.	  Adapted	  from	  [117].	  11 
	  12 
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553	  –	  602	   Leucine/Isoleucine	  zipper	  (LIZ)	  motifs	  















659	  –	  797	   SPRY1	  domain	  
Protein-­‐protein	  
interaction	  motif,	  
exact	  effect	  on	  RyR1	  
unknown	  
In	  silico	  analysis	  
-­‐-­‐	  





In	  silico	  analysis	  
[71]	  
1084	  –	  1207	   SPRY2	  domain	   Binding	  to	  DHPR	  α1s	  II-­‐III	  loop,	  activates	  RyR1	  




1272-­‐1455	   Divergent	  region	  2	  (D2)	  
Binding	  to	  DHPR	  and	  
responsible	  for	  




[21,	  32,	  33]	  
1430	  –	  1570	   SPRY3	  domain	  
Protein-­‐protein	  
interaction	  motif,	  
exact	  effect	  on	  RyR1	  
unknown	  
In	  silico	  analysis	  
-­‐-­‐	  
1773	  PPHHF	  





In	  silico	  analysis	  
[71]	  
1837	  –	  2168	   Binding	  to	  DHPR	   Activates	  RyR1	   Experimental	  studies	  
[25,	  35]	  
1861	  –	  2155	   Binding	  to	  S100A1	   Activates	  RyR1	   Experimental	  studies	  
[45]	  
1872	  –	  1922	   Low	  affinity	  Ca
2+	  




1975	  –	  1999	   Binding	  to	  calmodulin	  
Effect	  depends	  on	  
which	  form	  is	  bound	  
(apoCaM	  is	  a	  partial	  









an	  antagonist	  of	  RyR1)	  
1998	  FRSPP	  





In	  silico	  analysis	  
[71]	  

















[52,	  53,	  58]	  
2659	  –	  3720	   Binding	  to	  DHPR	   Activates	  RyR1	   Experimental	  studies	  
[25,	  35]	  
2843S	   Phosphorylation	  site	   Likely	  activates	  RyR1	   Experimental	  studies	  
[103]	  




3039	  –	  3075	   Leucine/Isoleucine	  zipper	  (LIZ)	  motifs	  
















3481	  –	  3485	   ASI	  region	   See	  above	   Experimental	  studies	  
[16,	  30,	  120]	  
3495	  –	  3502	  
Basic	  sequence	  
upstream	  from	  ASI	  
region	  
Possible	  binding	  to	  
DHPR	  β1a	  subunit,	  
may	  stabilize	  
interaction	  between	  
















Effect	  depends	  on	  
which	  form	  is	  bound	  
(apoCaM	  is	  a	  partial	  
agonist	  vs.	  CaCaM	  is	  




3616	  –	  3627	   Binding	  to	  S100A1	   Activates	  RyR1	   Experimental	  studies	  
[44]	  






site	   studies	  
3773	  –	  3873	   Binding	  to	  S100A1	   Activates	  RyR1	   Experimental	  studies	  
[45]	  
3865	  –	  3870	   ASII	  region	   Unknown	   Experimental	  studies	  
[16]	  








Unknown(?)	   Experimental	  studies	  
[88]	  
4080	  –	  4091	   Low	  affinity	  Ca
2+	  











4245	  –	  4378	   High	  affinity	  Ca
2+	  








4426	  –	  4622	   Binding	  to	  S100A1	   Activates	  RyR1	   Experimental	  studies	  
[45]	  
4490	  –	  4502	   High	  affinity	  Ca
2+	  











4861	  –	  4918	   Binding	  to	  triadin	   Activates	  RyR1	   Experimental	  studies	  
[60]	  
4895	  GGGIGD	  
4900	   Selectivity	  filter	  
Channel	  conductance	  







Abbreviations:	  MH,	  malignant	  hyperthermia;	  CCD,	  central	  core	  disease;	  DHPR,	  dihydropyridine	  1 
receptor;	  apoCaM,	  calmodulin	  with	  unbound	  calcium;	  CaCaM,	  calmodulin	  with	  bound	  calcium;	  AS,	  2 
alternatively	  spliced.	  3 
	  4 
	  5 











Amino	  acid	  range	  H	  
(human)/R	  (rabbit)	  
cDNA	  sequence	  








MH/CCD	  domain	  1	  
MH/CCD	  domain	  2	  
MH/CCD	  domain	  3	  
Stabilize	  closed	  conformation	   [121]	  	  
Alternative	  
splice	  variants	  
H	  3481-­‐3485	  	  	  ASI(-­‐)	  











SPRY	   H	  659-­‐797	  	  	  	  SPRY1	  
H	  1084-­‐1207	  	  SPRY2	  





domain;	  SPRY2	  identified	  as	  
binding	  DHPR	  α1s	  II-­‐III	  loop	  	  
	  
DHPR	  α1s	  II-­‐III	  
loop	  
H	  1076-­‐1112	  





MH/CCD	  domain	  2	  
Orthograde	  signaling	  
Contribute	  to	  skeletal	  EC	  






DHPR	  ß1	  	   H	  3495-­‐3502	  	  
R	  3201-­‐3661	  
ASI	  (-­‐)	   Strengthens	  effect	  of	  





H	  1272-­‐1455	   	   Tetrad	  formation	  enhanced	  
but	  sequence	  not	  sufficient	  
[21]	  
FKBP12	   H	  2458-­‐2468	   MH/CCD	  domain	  2	   Stabilizes	  closed	  state	   [52,	  53,	  
58]	  	  
Calmodulin	   H	  2937-­‐3225	  ApoCaM	  
H	  3553-­‐3662	  CaCaM	  
H	  3614-­‐3663	  Apo	  and	  
CaCaM	  





MH/CCD	  domain	  3	  
	   [41]	  












Triadin	   H	  4861-­‐4918	   MH/CCD	  domain	  3	   Rapid	  Ca2+	  release	   [60]	  
Kinases/	  
phosphotases	  
H	  552-­‐602	  PPI	  
H	  3039-­‐3075	  PKA	  
Leu/Ile	  zipper	  (LIZ)	  
motifs	  





Homer	   H	  801-­‐805	  
H	  1773-­‐1777	  
H	  1998-­‐2002	  
	   Enhances	  RyR1	  function	   [71]	  
Redox	  
sensitive	  Cys	  


















MH/CCD	  domain	  3	  
MH/CCD	  domain	  3	  
MH/CCD	  domain	  3	  
Low	  affinity,	  Ca2+	  inactivation	  
Low	  affinity	  Ca2+	  inactivation	  
Ca2+	  binding	  
High	  affinity	  Ca2+	  activation	  
[82,	  83,	  
87,	  119]	  	  
Abbreviations:	  H,	  human;	  R,	  rabbit;	  MH,	  malignant	  hyperthermia;	  CCD,	  central	  core	  disease;	  AS,	  1 
alternatively	  sliced;	  DHPR,	  dihydropyridine	  receptor.	  2 
	  3 






Table	  3.	  Recessive	  RYR1	  mutations	  and	  neuromuscular	  diseases.	  Genetic	  RYR1	  mutations	  and	  the	  1 
corresponding	  possible	  protein/ion	  binding	  domains	  affected	  are	  listed,	  along	  with	  a	  brief	  2 
description	  of	  clinical	  phenotypes.	  3 
RYR1	  Mutation	  
1	  


























100%	   Normal	   Cores	   	   [2]	  
c.325C>T	  
p.R109W	  





M402L	   50%	   Reduced	   CFTD	   	   [3]	  
c.1205T>C	  
p.M402T	  
















G1704S	   50%	   Slightly	  
reduced	  














100%	   -­‐	   MmD/MHS,	  
fiber	  type	  1	  
predominance	  
	  











M2423K	   50%	   Slightly	  
reduced	  

































































exon	  95	  skipped	  









100%	   -­‐	   MmD/rhabdo,	  


















































c.8342_8343∆TA	   H3981Y	   50%	   -­‐	   CNM	   None	  known	   [4]	  
c.12986C>A	  
p.A4329D	  


















































































p.Gly2898AspfsX54	   expressed	  
Abbreviations:	  c.,	  coding	  sequence;	  p.,	  protein	  sequence;	  X,	  stop	  codon;	  CNM,	  centronuclear	  1 
myopathy;	  CFTD,	  congenital	  fiber	  type	  disproportion;	  MmD,	  multi-­‐minicore	  disease;	  MHS,	  2 
malignant	  hyperthermia	  susceptibility;	  rhabdo,	  rhabdomyolysis;	  FSD,	  fiber-­‐size	  disproportion;	  3 
DHPR,	  dihydropyridine	  receptor;	  CaM,	  calmodulin.	  -­‐,	  data	  not	  available.	  4 
*	  compared	  with	  normal	  RyR1	  expression	  levels.	  Monoallelic	  refers	  to	  when	  only	  one	  RYR1	  allele	  5 
was	  seen	  on	  analysis	  of	  cDNA	  in	  patient	  muscle.	  A	  second	  ‘null’	  mutation	  likely	  exists	  in	  these	  6 
patients	  but	  has	  not	  been	  identified.	  7 
